Clinical significance of flash monitoring indicators in children with type 1 diabetes mellitus

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

A basic principle of the treatment of type 1 diabetes mellitus, along with insulin therapy and diet therapy, is regular self-monitoring of glycemia. Glucose meters are often used for daily self-monitoring, and devices for continuous and flash monitoring of glycemia have been used in recent years.

This review discusses the clinical aspects of the application of a glycemic monitoring system with periodic scanning (flash monitoring). The principle of operating the system and the main parameters obtained when using this system are described: time in the target range, time above and below the target range and their sub-ranges, indicators of glycemic variability and glycemic control, their normative levels, and their practical significance and relationship with the clinical aspects of the course of diabetes mellitus and prognosis of chronic complications.

The results of major international and domestic studies on the effectiveness of the flash monitoring system in different age groups are presented. The advantages of the second generation of flash glycemia monitoring sensors and results of clinical studies of the accuracy of this monitoring system in children and adult patients with diabetes mellitus are presented.

全文:

受限制的访问

作者简介

Irina Alimova

Smolensk State Medical University

Email: iri-alimova@yandex.ru
ORCID iD: 0000-0003-3230-1337
SPIN 代码: 4583-9822

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Smolensk

Alexandra Demyanenko

Smolensk State Medical University

编辑信件的主要联系方式.
Email: alex-glam@mail.ru
ORCID iD: 0000-0002-8787-6819
SPIN 代码: 6889-8349

MD, Cand. Sci. (Medicine), Associate Professor

俄罗斯联邦, Smolensk

参考

  1. Type 1 diabetes mellitus in children: clinical recommendations. In: Rubricator of clinical recommendations [Internet]. Moscow: Ministry of Health of the Russian Federation; 2023 [cited 2024 Mar 21]. Available from: https://cr.minzdrav.gov.ru/recomend/287_2
  2. Limbert C, Tinti D, Malik F, et al. ISPAD Clinical Practice Consensus Guidelines 2022: the delivery of ambulatory diabetes care to children and adolescents with diabetes. Pediatr Diabetes. 2022;23(8):1243–1269. doi: 10.1111/pedi.13417
  3. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. doi: 10.2337/dci19-0028
  4. Peterkova VA, Ametov AS, Mayorov AYu, et al. The scientific advisory board resolution: implementation of intermittently scanned continuous glucose monitoring in clinical practice to improve glycemic control. Diabetes Mellitus. 2021;24(2):185–192. EDN: MTSCZE doi: 10.14341/DM12753
  5. Suplotova LA, Sudnitsyna AS, Romanova NV, Shestakova MV. Time in range is a tool for assessing the quality of glycemic control in diabetes. Diabetes Mellitus. 2021;24(3):282–290. EDN: LRJDHM doi: 10.14341/DM12703
  6. Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA1c for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D exchange. Diabetes Care. 2017;40(12):1622–1630. doi: 10.2337/dc17-1624
  7. Bergenstal RM, Beck RW, Close KL, et al. Glucose management indicator (GMI): a new term for estimating A1C from continuous glucose monitoring. Diabetes Care. 2018;41(11):2275–2280. doi: 10.2337/dc18-1581
  8. Dedov II, Shestakova MV, Mayorov AYu, et al. Standards of specialized diabetes care. Dedov II, Shestakova MV, Mayorov AYu, editors. 11th edition. Diabetes mellitus. 2023;26(S2):1–157. EDN: DCKLCI doi: 10.14341/DM13042
  9. Campbell F, Bolinder J. FreeStyle Libre™ use for self-management of diabetes in teenagers and young adults. Diabetes. 2018;67(Suppl. 1):158–LB. doi: 10.2337/db18-158-LB
  10. Messaaoui A, Tenoutasse S, Crenier L. Flash glucose monitoring accepted in daily life of children and adolescents with type 1 diabetes and reduction of severe hypoglycemia in real-life use. Diabetes Technol Ther. 2019;21(6):329–335. doi: 10.1089/dia.2018.0339
  11. Al Hayek AA, Robert AA, Al Dawish MA. Evaluation of FreeStyle Libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes. 2017;10:1179551417746957. doi: 10.1177/1179551417746957
  12. Leiva-Gea I, Vázquez JG, Jurado FRL, et al. Introduction of flash glucose monitoring in children with type 1 diabetes: experience of a single-centre in Spain. ESPE Abstracts. 2019;(92):LB–20.
  13. Mulinacci G, Alonso GT, Snell-Bergeon JK, Shah VN. Glycemic outcomes with early initiation of continuous glucose monitoring system in recently diagnosed patients with type 1 diabetes. Diabetes Technol Ther. 2019;21(1):6–10. doi: 10.1089/dia.2018.0257
  14. Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379–387. doi: 10.1001/jama.2016.19976 Corrected and republished from: JAMA. 2017;317(18):1912. doi: 10.1001/jama.2017.4657
  15. Laptev DN, Emelyanov AO, Andrianova EA, at al. The use of Flash glucose monitoring in children with type 1 diabetes mellitus in real clinical practice. Diabetes Mellitus. 2021;24(6):504–510. EDN: TIEVHC doi: 10.14341/DM12817
  16. Laptev DN, Bezlepkina OB, Demina ES, et al. The results of clinical testing of the freestyle libre system in children with type 1 diabetes mellitus: improved glycemic control combined with a reduced risk of severe hypoglycemia and diabetic ketoacidosis. Problems of Endocrinology. 2022;68(3):86–92. EDN: MDDFFV doi: 10.14341/probl12877
  17. Aouchiche K, Bernoux D, Baechler Sadoul E, et al. Impact of continuous glucose monitoring on everyday life of young children with type 1 diabetes and their parents: an evaluation of 114 families. Prim Care Diabetes. 2024;18(1):91–96. doi: 10.1016/j.pcd.2023.11.002
  18. Elbalshy M, Haszard J, Smith H, et al. Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials. Diabet Med. 2022;39(8):e14854. doi: 10.1111/dme.14854
  19. Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: a European analysis of over 60 million glucose tests. Diabetes Res Clin Pract. 2018;137:37–46. doi: 10.1016/j.diabres.2017.12.015
  20. Demyanenko AN, Alimova IL. Glycemic variability as a risk factor for impaired glycemic recognition syndrome. In: Fundamental and clinical diabetology in the 21st century: from theory to practice: сollection of abstracts of the conference on the treatment and diagnosis of diabetes mellitus. Moscow: 2022. P. 44. (In Russ.) EDN: DAJIKK doi: 10.14341/Conf7-8.09.22-44
  21. Demyanenko AN, Alimova IL. Features of carbohydrate metabolism in adolescent children with impaired recognition of hypoglycemia when using different schemes of glycemia monitoring. In: Innovative technologies in endocrinology: collection of abstracts of IV (XXVII) National Congress of Endocrinologists “Innovative technologies in endocrinology”; 22–25 Sept 2021; Moscow. Available from: https://aston-health.com/press-czentr/novosti/iv-(xxvii)-naczionalnyij-kongress-endokrinologov-%C2%ABinnovaczionnyie-texnologii-v-endokrinologii%C2%BB.html (In Russ.)
  22. Choudhary P, Campbell F, Joule N, et al. A type 1 diabetes technology pathway: consensus statement for the use of technology in type 1 diabetes. Diabet Med. 2019;36(5):531–538. doi: 10.1111/dme.13933
  23. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021;27(6):505–537. doi: 10.1016/j.eprac.2021.04.008
  24. Alva S, Bailey T, Brazg R, et al. Accuracy of a 14-day factory-calibrated continuous glucose monitoring system with advanced algorithm in pediatric and adult population with diabetes. J Diabetes Sci Technol. 2022;16(1):70–77. doi: 10.1177/1932296820958754
  25. Bailey T, Bode BW, Christiansen MP, et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17(11):787–794. doi: 10.1089/dia.2014.0378
  26. Leelarathna L, Evans ML, Neupane S, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med. 2022;387(16):1477–1487. doi: 10.1056/NEJMoa2205650

补充文件

附件文件
动作
1. JATS XML
下载
2. Fig. 1. Ambulatory glucose profile in patient K., born in 2009, with a diagnosis of type 1 diabetes mellitus. Green indicates time in the target range (91%), red indicates time below the target range (1%), yellow indicates time above the target range (8%). The duration of wearing the sensor (14 days), the time of sensor activity (88%), the glucose level control indicator (6.3%) and the coefficient of glycemic variability (26.1%) are indicated. All indicators are in target values

下载 (455KB)
索引源数据

版权所有 © Eco-Vector, 2024

许可 URL: https://eco-vector.com/for_authors.php#07
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г.


##common.cookie##